6. パーキンソン病 Parkinson disease Clinical trials / Disease details


臨床試験数 : 2,298 薬物数 : 2,218 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202

  
15 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-004344-19-DE
(EUCTR)
07/02/201727/09/2016An international trial of deferiprone in patients with Parkinson’s diseaseA Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients with Parkinson’s Disease - LA48-0215 Parkinson’s disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Deferiprone 600 mg delayed release tablet
INN or Proposed INN: DEFERIPRONE
ApoPharmaNULLNot Recruiting Female: yes
Male: yes
140 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noFrance;Canada;Germany;United Kingdom
2NCT02728843
(ClinicalTrials.gov)
October 12, 201631/3/2016Study of Parkinson's Early Stage With DeferiproneA Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients With Parkinson's DiseaseParkinson's DiseaseDrug: Deferiprone;Drug: PlaceboApoPharmaNULLCompleted18 Years80 YearsAll140Phase 2Canada;France;Germany;United Kingdom
3EUCTR2015-003679-31-NL
(EUCTR)
09/08/201624/05/2016New therapeutic strategy in Parkinson’s diseaseConservative iron chelation as a disease-modifying strategy in Parkinson’s disease - FAIRPARK II De Novo Parkinson’s disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: Deferiprone DR
INN or Proposed INN: DEFERIPRONE
Centre Hospitalier Régional et Universitaire de LilleNULLNot RecruitingFemale: yes
Male: yes
338Phase 2Portugal;Czech Republic;Spain;Austria;Netherlands
4EUCTR2015-004344-19-FR
(EUCTR)
29/06/201620/04/2016An international trial of deferiprone in patients with parkinson’s diseaseA Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients with Parkinson’s Disease - LA48-0215 Parkinson’s disease
MedDRA version: 19.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Deferiprone 600 mg delayed release tablet
INN or Proposed INN: DEFERIPRONE
ApoPharma Inc.NULLNot Recruiting Female: yes
Male: yes
140 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited States;France;Canada;Germany;Italy;United Kingdom
5EUCTR2015-003679-31-CZ
(EUCTR)
23/06/201628/01/2016New therapeutic strategy in Parkinson’s diseaseConservative iron chelation as a disease-modifying strategy in Parkinson’s disease - FAIRPARK II De Novo Parkinson’s disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: Deferiprone DR
INN or Proposed INN: DEFERIPRONE
Centre Hospitalier Régional et Universitaire de LilleNULLNot RecruitingFemale: yes
Male: yes
338Phase 2Portugal;Czech Republic;Spain;Austria;Netherlands
6EUCTR2015-003679-31-PT
(EUCTR)
18/04/201628/01/2016New therapeutic strategy in Parkinson’s diseaseConservative iron chelation as a disease-modifying strategy in Parkinson’s disease - FAIRPARK II De Novo Parkinson’s disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: Deferiprone DR
INN or Proposed INN: DEFERIPRONE
Centre Hospitalier Régional et Universitaire de LilleNULLNot RecruitingFemale: yes
Male: yes
338Phase 2Portugal;Czech Republic;Spain;Austria;Netherlands
7EUCTR2015-003679-31-AT
(EUCTR)
06/04/201611/01/2016New therapeutic strategy in Parkinson’s diseaseConservative iron chelation as a disease-modifying strategy in Parkinson’s disease - FAIRPARK II De Novo Parkinson’s disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: Deferiprone DR
INN or Proposed INN: DEFERIPRONE
Centre Hospitalier Régional et Universitaire de LilleNULLNot RecruitingFemale: yes
Male: yes
372Phase 2Portugal;France;Czech Republic;Spain;Austria;Netherlands;Germany;United Kingdom
8EUCTR2015-004344-19-GB
(EUCTR)
31/03/201616/02/2016An international trial of deferiprone in patients with Parkinson’s diseaseA Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients with Parkinson’s Disease - LA48-0215 Parkinson’s disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Deferiprone 600 mg delayed release tablet
INN or Proposed INN: DEFERIPRONE
ApoPharmaNULLNot RecruitingFemale: yes
Male: yes
140Phase 2France;Canada;Germany;United Kingdom
9EUCTR2015-003679-31-ES
(EUCTR)
21/03/201613/01/2016New therapeutic strategy in Parkinson?s diseaseConservative iron chelation as a disease-modifying strategy in Parkinson?s disease: a multicentre, parallel-group, placebo-controlled, randomized clinical trial of deferiprone - FAIRPARK II De Novo Parkinson?s disease
MedDRA version: 18.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Ferriprox 500 mg
Product Name: Deferiprone DR
INN or Proposed INN: DEFERIPRONE
Centre Hospitalier Régional et Universitaire de LilleNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
338Phase 3Spain
10NCT02655315
(ClinicalTrials.gov)
February 9, 20167/1/2016Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's DiseaseConservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease. European Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of DeferiproneParkinson DiseaseDrug: Deferiprone;Drug: PlaceboUniversity Hospital, LilleEuropean Commission;ApoPharmaActive, not recruitingN/A80 YearsAll372Phase 2Austria;Czechia;France;Germany;Netherlands;Portugal;Spain;United Kingdom;Czech Republic
11EUCTR2015-003679-31-FR
(EUCTR)
25/01/201625/02/2016New therapeutic strategy in Parkinson’s diseaseConservative iron chelation as a disease-modifying strategy in Parkinson’s disease - FAIRPARK II De Novo Parkinson’s disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: Deferiprone DR
INN or Proposed INN: DEFERIPRONE
Centre Hospitalier Régional et Universitaire de LilleNULLNot RecruitingFemale: yes
Male: yes
338Phase 2Portugal;France;Czech Republic;Spain;Austria;Netherlands
12NCT01539837
(ClinicalTrials.gov)
February 201222/2/2012A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's DiseaseA Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's DiseaseParkinson's DiseaseDrug: Deferiprone 20mg;Drug: Placebo;Drug: Deferiprone 30mgImperial College LondonNULLCompleted50 Years75 YearsAll22Phase 2United Kingdom
13EUCTR2011-001148-31-GB
(EUCTR)
13/09/201117/08/2011A pilot clinical trial with the iron chelator Deferiprone in Parkinson's disease - Pilot clinical trial iron chelator Deferiprone in Parkinson's Vs1A pilot clinical trial with the iron chelator Deferiprone in Parkinson's disease - Pilot clinical trial iron chelator Deferiprone in Parkinson's Vs1 Parkinson's diseaseTrade Name: Ferrprox (Deferiprone)
Product Name: Deferiprone (Ferriprox)
INN or Proposed INN: Deferiprone
Imperial College LondonNULLNot Recruiting Female: yes
Male: yes
48 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited Kingdom
14NCT02880033
(ClinicalTrials.gov)
February 20113/8/2016Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating LymphocytesModulation of Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes of Patients With Parkinson's Disease or Amyotrophic Lateral SclerosisParkinson's Disease;Amyotrophic Lateral Sclerosis;Oxidative Stress;Iron OverloadDrug: deferiprone;Drug: placeboUniversity Hospital, LilleNULLCompleted18 Years80 YearsAll90N/AFrance
15NCT00943748
(ClinicalTrials.gov)
October 200920/7/2009Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's DiseaseEfficacy and Safety of the Iron Chelator Deferiprone on Iron Overload in the Brain in Parkinson's DiseaseParkinson's DiseaseDrug: deferiprone;Drug: placeboUniversity Hospital, LilleNULLCompleted30 Years80 YearsBoth40Phase 2/Phase 3France